Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes

Neurochemistry International

Volumn 56, Issue 3, 2010, Pages 443-450

  Duran Vilaregut, Joaquim ^a,b   del Valle, Jaume ^a,b   Manich, Gemma ^a   Junyent, Fèlix ^a,b   Camins, Antoni ^a,b   Pallàs, Mercè ^a,b   Pelegrí, Carme ^a,b   Vilaplana, Jordi ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Apoptosis; Huntington's disease; Neurodegeneration; Rat; Striatum; TUNEL

Indexed keywords

3 NITROPROPIONIC ACID; CASPASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN DAMAGE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL; NERVE DEGENERATION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; ASTROCYTES; CASPASE 3; CONVULSANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUNTINGTON DISEASE; IN SITU NICK-END LABELING; MALE; NERVE DEGENERATION; NEURONS; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 77049099072     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.12.001     Document Type: Article

References (53)

1. Acarin L., Villapol S., Faiz M., Rohn T.T., Castellano B., González B. Caspase-3 activation in astrocytes following postnatal excitotoxic damage correlates with cytoskeletal remodeling but not with cell death or proliferation. Glia 2007, 55:954-965.
2. Almeida S., Domingues A., Rodrigues L., Oliveira C.R., Rego A.C. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol. Dis. 2004, 17:435-444.
3. Almeida S., Brett A.C., Góis I.N., Oliveira C.R., Rego A.C. Caspase-dependent and -independent cell death induced by 3-nitropropionic acid in rat cortical neurons. J. Cell. Biochem. 2006, 98:93-101.
4. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
5. Bignami A., Dahl D. Specificity of the glial fibrillary acidic protein for astroglia. J. Histochem. Cytochem. 1977, 25:466-469.
6. Bizat N., Hermel J.M., Boyer F., Jacquard C., Créminon C., Ouary S., Escartin C., Hantraye P., Kajewski S., Brouillet E. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J. Neurosci. 2003, 23:5020-5030.
7. Bizat N., Hermel J.M., Humbert S., Jacquard C., Créminon C., Escartin C., Saudou F., Krajewski S., Hantraye P., Brouillet E. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J. Biol. Chem. 2003, 278:43245-43253.
8. Blum D., Gall D., Cuvelier L., Schiffmann S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 2001, 12:1769-1772.
9. Bröker L.E., Kruyt F.A., Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 2005, 11:3155-3162.
10. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427-468.
11. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 2005, 95:1521-1540.
12. Charvet C., Alberti I., Luciano F., Jacquel A., Bernard A., Auberger P., Deckert M. Proteolytic regulation of Forkhead transcription factor FOXO3a by caspase-3-like proteases. Oncogene 2003, 22:4557-4568.
13. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 2000, 6:797-801.
14. Del Río P., Massieu L. Mild mitochondrial inhibition in vivo enhances glutamate-induced neuronal damage through calpain but not caspase activation: role of ionotropic glutamate receptors. Exp. Neurol. 2008, 212:179-188.
15. Diwakarla S., Mercer L.D., Kardashsyan L., Chu P.W., Shin Y.S., Lau C.L., Hughes M.L., Nagley P., Beart P.M. GABAergic striatal neurons exhibit caspase-independent, mitochondrially mediated programmed cell death. J. Neurochem. 2009, 109(Suppl. 1):198-206.
16. Duan W., Guo Z., Mattson M.P. Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid. Exp. Neurol. 2000, 165:1-11.
17. Duran-Vilaregut J., del Valle J., Camins A., Pallàs M., Pelegrí C., Vilaplana J. Blood-brain barrier disruption in the striatum of rats treated with 3-nitropropionic acid. Neurotoxicology 2009, 30:136-143.
18. Eng L.F., Ghirnikar R.S., Lee Y.L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 2000, 25:1439-1451.
19. Galas M.C., Bizat N., Cuvelier L., Bantubungi K., Brouillet E., Schiffmann S.N., Blum D. Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiol. Dis. 2004, 15:152-159.
20. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 1992, 119:493-501.
21. Gil J.M., Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 2008, 27:2803-2820.
22. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
23. Hedreen J.C., Folstein S.E. Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 1995, 54:105-120.
24. Hickey M.A., Chesselet M.F. Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:255-265.
25. Johnson E.A., Svetlov S.I., Wang K.K., Hayes R.L., Pineda J.A. Cell-specific DNA fragmentation may be attenuated by a survivin-dependent mechanism after traumatic brain injury in rats. Exp. Brain Res. 2005, 167:17-26.
26. Lei B., Popp S., Capuano-Waters C., Cottrell J.E., Kass I.S. Lidocaine attenuates apoptosis in the ischemic penumbra and reduces infarct size after transient focal cerebral ischemia in rats. Neuroscience 2004, 125:691-701.
27. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
28. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
29. McLaughlin B. The kinder side of killer proteases: caspase activation contributes to neuroprotection and CNS remodeling. Apoptosis 2004, 9:111-121.
30. Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
31. Nicotera P., Leist M., Manzo L. Neuronal cell death: a demise with different shapes. Trends Pharmacol. Sci. 1999, 20:46-51.
32. Nishino H., Shimano Y., Kumazaki M., Sakurai T. Chronically administered 3-nitropropionic acid induces striatal lesions attributed to dysfunction of the blood-brain barrier. Neurosci. Lett. 1995, 186:161-164.
33. Nishino H., Kumazaki M., Fukuda A., Fujimoto I., Shimano Y., Hida H., Sakurai T., Deshpande S.B., Shimizu H., Morikawa S., Inubushi T. Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosci. Res. 1997, 27:343-355.
34. Noyan-Ashraf M.H., Brandizzi F., Juurlink B.H. Constitutive nuclear localization of activated caspase 3 in subpopulations of the astroglial family of cells. Glia 2005, 49:588-593.
35. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
36. Oomman S., Strahlendorf H., Dertien J., Strahlendorf J. Bergmann glia utilize active caspase-3 for differentiation. Brain Res. 2006, 1078:19-34.
37. Perry G., Nunomura A., Lucassen P., Lassmann H., Smith M.A. Apoptosis and Alzheimer's disease. Science 1998, 282:1268-1269.
38. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 1995, 15:3775-3787.
39. Raina A.K., Hochman A., Zhu X., Rottkamp C.A., Nunomura A., Siedlak S.L., Boux H., Castellani R.J., Perry G., Smith M.A. Abortive apoptosis in Alzheimer's disease. Acta Neuropathol. 2001, 101:305-310.
40. Raina A.K., Zhu X., Shimohama S., Perry G., Smith M.A. Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept. Cell Biochem. Biophys. 2003, 39:249-255.
41. Sánchez I., Xu C.J., Juo P., Kakizaka A., Blenis J., Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999, 22:623-633.
42. Sanchez Mejia R.O., Friedlander R.M. Caspases in Huntington's disease. Neuroscientist 2001, 7:480-489.
43. Schwerk C., Schulze-Osthoff K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem. Pharmacol. 2003, 66:1453-1458.
44. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397:441-446.
45. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., Reed J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95). Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58:5315-5320.
46. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell. Biol. 2008, 9:231-241.
47. Thuret G., Chiquet C., Herrag S., Dumollard J.M., Boudard D., Bednarz J., Campos L., Gain P. Mechanisms of staurosporine induced apoptosis in a human corneal endothelial cell line. Br. J. Ophthalmol. 2003, 87:346-352.
48. Túnez I., Collado J.A., Medina F.J., Peña J., del C., Muñoz M., Jimena I., Franco F., Rueda I., Feijóo M., Muntané J., Montilla P. 17 beta-estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats. Neurochem. Int. 2006, 48:367-373.
49. Vis J.C., Schipper E., de Boer-van Huizen R.T., Verbeek M.M., de Waal R.M., Wesseling P., ten Donkelaar H.J., Kremer B. Expression pattern of apoptosis-related markers in Huntington's disease. Acta Neuropathol. 2005, 109:321-328.
50. Walling H.W., Baldassare J.J., Westfall T.C. Molecular aspects of Huntington's disease. J. Neurosci. Res. 1998, 54:301-308.
51. Wang K.K. Calpain and caspase: can you tell the difference?. Trends Neurosci. 2000, 23:20-26.
52. Yang L., Sugama S., Mischak R.P., Kiaei M., Bizat N., Brouillet E., Joh T.H., Beal M.F. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol. Dis. 2004, 17:250-259.
53. Zhu X., Raina A.K., Perry G., Smith M.A. Apoptosis in Alzheimer disease: a mathematical improbability. Curr. Alzheimer Res. 2006, 3:393-396.